Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non Operating Income: 2021-2025

Historic Non Operating Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to $1.6 million.

  • Amylyx Pharmaceuticals' Non Operating Income fell 44.50% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 49.37%. This contributed to the annual value of $12.6 million for FY2024, which is 18.72% down from last year.
  • Amylyx Pharmaceuticals' Non Operating Income amounted to $1.6 million in Q3 2025, which was up 16.05% from $1.4 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Non Operating Income's 5-year high stood at $4.5 million during Q4 2023, with a 5-year trough of -$3.3 million in Q2 2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Non Operating Income averaged around $3.0 million, with its median value being $3.5 million (2023).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Non Operating Income surged by 8,610.34% in 2022 and then crashed by 60.57% in 2025.
  • Amylyx Pharmaceuticals' Non Operating Income (Quarterly) stood at -$29,000 in 2021, then surged by 8,610.34% to $2.5 million in 2022, then soared by 84.04% to $4.5 million in 2023, then crashed by 45.55% to $2.5 million in 2024, then tumbled by 44.50% to $1.6 million in 2025.
  • Its Non Operating Income stands at $1.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.9 million for Q1 2025.